Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer

Share This Post

August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).

ARASENS (NCT02799602), a randomised, multicenter, double-blind, placebo-controlled clinical trial involving 1306 patients with mHSPC, served as the foundation for the effectiveness. Patients were randomly assigned to receive either docetaxel plus placebo or darolutamide 600 mg orally twice daily in addition to docetaxel 75 mg/m2 intravenously given every three weeks for up to six cycles. All patients had bilateral orchiectomy or concurrent administration of a gonadotropin-releasing hormone analogue.

The overall survival rate was the main efficacy metric (OS). Another metric for efficacy was the time until pain began to progress. In the darolutamide plus docetaxel arm, the median OS was not attained (NR) (95% CI: NR, NR), whereas in the docetaxel plus placebo arm, the median OS was 48.9 months (95% CI: 44.4, NR) (HR 0.68; 95% CI: 0.57, 0.80; p0.0001). Time to pain progression was statistically significantly delayed by treatment with darolutamide plus docetaxel (HR 0.79; 95% CI: 0.66, 0.95; 1-sided p=0.006).

The patients’ average age ranged from 41 to 89, and 17% of them were 75 or older. The following list of selected demographics was provided: 36% Asian, 4% Black or African American, 52% White, 7% Hispanic/Latino. Patients who had M1a disease (3%) had it spread to distant lymph nodes, 83% had M1b disease (83%), and 14% had M1c disease (spread to organs).

Constipation, a decrease in appetite, a rash, bleeding, a rise in weight, and hypertension were the most frequent adverse effects reported by patients (incidence 10% with a 2% increase above placebo with docetaxel). Anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased AST, elevated ALT, and hypocalcemia were the most prevalent abnormalities seen in laboratory tests (30%).

For mHSPC, a dose of 600 mg (two 300 mg tablets) of darolutamide twice daily with food is advised until intolerable toxicity or disease progression. For up to 6 cycles, docetaxel 75 mg/m2 is intravenously injected every 3 weeks. Within six weeks after the initiation of the darolutamide treatment, the first dosage of docetaxel should be given.

View full prescribing information for Nubeqa.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/